Prescription medicine
Angiotensin ii Brand names: Giapreza
Angiotensin ii (Giapreza) is a prescription medicine with an FDA approval on record since 2017. FDA's NDC Directory lists it from 1 generic labeler.
- Generic listed
Check it at the source: the angiotensin ii FDA label on DailyMed (effective July 22, 2026, La Jolla Pharmaceutical Company); the NDA 209360 record on Drugs@FDA; every angiotensin ii label on DailyMed.
Highlights of the record
FDA label of July 22, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageINDICATIONS AND USAGE GIAPREZA increases blood pressure in adults with septic or other distributive shock [see Clinical Studies (14)].
Forms and strengths
- 0.5 mg/ml
- 2.5 mg/ml
Injection.
On the market
- Earliest approval on file
- December 21, 2017 Giapreza, La Jolla Pharma; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 1 first June 3, 2025; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 1 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- January 6, 2037 Giapreza injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 297 through July 30, 2026
What is angiotensin ii used for?
From the label: indications and usageINDICATIONS AND USAGE GIAPREZA increases blood pressure in adults with septic or other distributive shock [see Clinical Studies (14)]. GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.
FDA pharmacologic class: Vasoconstrictor.
Source: FDA drug label (Giapreza), La Jolla Pharmaceutical Company, effective July 22, 2026 (SPL set c265d69a-3efe-4107-9a9e-e6fd3d531c48), via openFDA; the full label on DailyMed
Is there a generic for angiotensin ii (Giapreza)?
The FDA approved the first generic angiotensin ii on June 3, 2025. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists angiotensin ii from 1 labeler under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 11 patents for Giapreza injection, the last expiring on January 6, 2037. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2017 earliest approval on file
- 2025 first generic approved
- 2037 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for angiotensin ii?
The FDA Adverse Event Reporting System holds 297 reports that list angiotensin ii among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 94 are coded as a death and 116 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other vasoconstrictors
- the pharmacologic class, with prices and generics
- Angiotensin ii side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other